LUCD vs. SMTI, AVR, RCEL, LUNG, ELMD, INGN, ZYXI, LAKE, DRTS, and OBIO
Should you be buying Lucid Diagnostics stock or one of its competitors? The main competitors of Lucid Diagnostics include Sanara MedTech (SMTI), Anteris Technologies Global (AVR), AVITA Medical (RCEL), Pulmonx (LUNG), Electromed (ELMD), Inogen (INGN), Zynex (ZYXI), Lakeland Industries (LAKE), Alpha Tau Medical (DRTS), and Orchestra BioMed (OBIO). These companies are all part of the "medical equipment" industry.
Lucid Diagnostics vs.
Lucid Diagnostics (NASDAQ:LUCD) and Sanara MedTech (NASDAQ:SMTI) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, media sentiment, profitability, valuation, dividends, analyst recommendations, risk and community ranking.
Lucid Diagnostics received 15 more outperform votes than Sanara MedTech when rated by MarketBeat users. Likewise, 67.92% of users gave Lucid Diagnostics an outperform vote while only 58.33% of users gave Sanara MedTech an outperform vote.
Lucid Diagnostics presently has a consensus target price of $3.63, indicating a potential upside of 148.29%. Sanara MedTech has a consensus target price of $47.00, indicating a potential upside of 39.51%. Given Lucid Diagnostics' stronger consensus rating and higher probable upside, research analysts plainly believe Lucid Diagnostics is more favorable than Sanara MedTech.
74.0% of Lucid Diagnostics shares are owned by institutional investors. Comparatively, 8.1% of Sanara MedTech shares are owned by institutional investors. 8.8% of Lucid Diagnostics shares are owned by company insiders. Comparatively, 54.1% of Sanara MedTech shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Lucid Diagnostics has a beta of 1.49, indicating that its stock price is 49% more volatile than the S&P 500. Comparatively, Sanara MedTech has a beta of 1.57, indicating that its stock price is 57% more volatile than the S&P 500.
Sanara MedTech has a net margin of -10.71% compared to Lucid Diagnostics' net margin of -1,069.87%. Lucid Diagnostics' return on equity of 0.00% beat Sanara MedTech's return on equity.
Sanara MedTech has higher revenue and earnings than Lucid Diagnostics. Sanara MedTech is trading at a lower price-to-earnings ratio than Lucid Diagnostics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Lucid Diagnostics had 4 more articles in the media than Sanara MedTech. MarketBeat recorded 4 mentions for Lucid Diagnostics and 0 mentions for Sanara MedTech. Lucid Diagnostics' average media sentiment score of 0.01 beat Sanara MedTech's score of 0.00 indicating that Lucid Diagnostics is being referred to more favorably in the media.
Summary
Lucid Diagnostics beats Sanara MedTech on 11 of the 18 factors compared between the two stocks.
Get Lucid Diagnostics News Delivered to You Automatically
Sign up to receive the latest news and ratings for LUCD and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Lucid Diagnostics Competitors List
Related Companies and Tools
This page (NASDAQ:LUCD) was last updated on 2/22/2025 by MarketBeat.com Staff
